Urothelial Cancer

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.

In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.

Roswell Park Comprehensive Cancer Center announces the release of an operative surgical manual for surgeons performing bladder cancer surgeries.

The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC.

The NCCN has included tumor-informed multiplex PCR ctDNA-MRD testing in the treatment approach for patients with MIBC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Check out some of the top oncology news and trends of the week.

OncLive spoke with urothelial cancer experts during Bladder Cancer Awareness Month to understand the current and future treatment landscape.

Durvalumab plus BCG maintained overall survival and quality of life in high-risk NMIBC at 5 years.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved durvalumab in combination with BCG for the treatment of adult patients with BCG-naive, high-risk NMIBC.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The CHMP granted a positive opinion to perioperative pembrolizumab/enfortumab vedotin as well as pembrolizumab and berahyaluronidase alfa in MIBC.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A supplemental BLA for nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease is under review by the FDA.

Stephanie A Berg, DO, discusses frequent UTIs in women and when bladder cancer referral may be appropriate.